

PORT CFNZ

2014 National Data Registry





The Port CFNZ National Data Registry is a research project of
Cystic Fibrosis New Zealand.

For further information about the CFNZ
visit www.cfnz.org.nz

The production of this Data Registry is funded through a conditional
grant from



Source of Data: Children, young persons and adults with Cystic Fibrosis in New Zealand who have consented to have their data recorded as part of this national registry

Suggested Citation: PORT CFNZ National Data Registry, 2014 Registry Report, Cystic Fibrosis New Zealand.



Table of Contents

| | |
|--------------------------------------|-------|
| Introduction & Acknowledgements..... | 6 |
| CF Clinics in New Zealand..... | 7 |
| Notes to the Registry..... | 8 |
| Key results at a glance..... | 9 |
| Demographics..... | 10-11 |
| Genotype..... | 12 |
| Respiratory..... | 13 |
| Nutrition..... | 14-16 |
| Medications..... | 17 |
| Microbiology..... | 18-20 |
| IV Episodes..... | 21 |
| Airway Clearance Techniques..... | 22-24 |
| CF-Related Diabetes..... | 25-26 |
| Glossary of Terms..... | 27 |
| Port CFNZ Primary Contacts..... | 27 |

Introduction & Acknowledgements

The Cystic Fibrosis New Zealand and the PORT CFNZ Steering Committee, are pleased to present The National Cystic Fibrosis Data Registry 2014 Report; data collected on children, young persons and adults with Cystic Fibrosis in New Zealand.

We would like to thank:

- The Nurses, Specialists and Administrators who have worked to enter data enabling a detailed analysis for NZ – presented in this report.
- Shares in Life Foundation for providing pivotal funding for database and data entry.
- Canterbury District Health Board for their ongoing commitment to maintain the registry.
- Above all, the children and adults with CF and their families for participating in this process.

This fourth registry report continues to give an accurate picture of people with CF and outcomes for New Zealand with greater than 95% opting to provide anonymous data.

Development of the database will lead to slightly different questions used next year, written exclusively with the New Zealand clinical environment in mind and provide more accurate information for our environment.

We hope you continue to find the information in the report informative and useful.

Associate Professor Cass Byrnes

Dr Richard Laing

Chair Port CFNZ Steering Committee

Port CFNZ Principal Investigator

Port CFNZ Steering Committee

Assoc.Prof Cass Byrnes (Chair)

Starship Children's Hospital &
University of Auckland

Dr Richard Laing (PI)

Christchurch Hospital, Christchurch

Dr Mark O'Carroll

Auckland Hospital and Greenlane Centre

Dr Julian Vyas

Starship Children's Hospital, Auckland

Jan Tate

Starship Children's Hospital, Auckland

Tory Crowder

Christchurch Hospital, Christchurch

Robyn Beach

Christchurch Hospital, Christchurch

Viv Isles

Christchurch Hospital, Christchurch

Belinda Burnett

CEO, Cystic Fibrosis New Zealand

CF Clinics in New Zealand

Northland (Paediatrics)

Whangarei Hospital, Whangarei

Auckland (Paediatrics and Adults)

Starship Children's Health
Greenlane Clinical Centre

Waikato (Paediatrics and Adults)

Waikato Hospital, Hamilton

Taranaki (Paediatrics)

Taranaki Base Hospital, New Plymouth

Bay of Plenty (Paediatrics)

Tauranga Hospital, Tauranga
Whakatane Hospital, Whakatane
Lakes Hospital, Rotorua

Central Districts (Paediatrics and Adults)

Whanganui Hospital, Whanganui
Palmerston North Hospital, Palmerston North

Hawkes Bay (Paediatrics and Adults)

Hawkes Bay District Hospital, Hastings
Tairāwhiti Hospital, Gisborne

Wellington (Paediatrics and Adults)

Capital and Coast Hospital, Wellington
Hutt Valley Hospital, Lower Hutt

Nelson/ Marlborough (Paediatrics and Adults)

Nelson Hospital, Nelson
Wairau Hospital, Blenheim

Canterbury/ Westland (Paediatrics and Adults)

Christchurch Hospital, Christchurch

Otago (Paediatrics and Adults)

Dunedin Hospital, Dunedin

Southland (Paediatrics and Adults)

Kew Hospital, Invercargill

Notes to the Registry

The Data registry gives national statistics. New Zealand has a total CF population comparative to a single clinic in USA/UK. Statistically accurate and relevant data for smaller clinics is difficult given the smaller numbers.

Our smaller population provides significant challenges to statistical interpretation as 'outliers' in terms of late diagnoses and key markers will have an impact on outcomes reported given the smaller numbers. Some decisions were made by the steering committee to exclude those outlier ages and statistics in order to give a more accurate picture of the overall patient outcomes for the country.

The brief commentary provided throughout this report reflects opinion based on our data, and when cited as compared to other registries these are from Australia, UK and USA in the main.

The NZ registry data is becoming more robust and accurate, **we welcome its use in audit and research projects**. A proposal for a project involving this national data base can be made in writing using the form found on the CFNZ website the PORTCFNZ steering committee.

Link: <http://www.cfnz.org.nz/our-services/library/downloads/#other>

Port CF Steering Committee
C/- CFNZ
P O Box 8241
Riccarton
Christchurch


Administrator: julie@cfnz.org.nz

Key Indicators

| | 2014 | 2013 | 2012 | 2011 |
|---------------------------|--------------|--------------|--------------|--------------|
| CF patients registered | 443 | 444 | 423 | 415 |
| Diagnosis age <1 year | 7 | 5 | 11 | 11 |
| Diagnosis age >16 years | 2 | 3 | 2 | |
| Age in years; median | 18.11 | 17.55 | 16.15 | 15.71 |
| PWCF aged >16 years | 247 55.8% | 239 53.8% | 214 50.6% | 206 49.6% |
| Males | 240 54.2% | 240 54.1% | 228 53.9% | 226 54.6% |
| Genotyped | 429 96.8% | 426 95.9% | 407 96.2% | 364 87.7% |
| Median FEV1 (% predicted) | 85.1% | 84.3% | 84.5% | 80.5% |
| <16 years | 97.7% | 96.6% | 97.2% | 91.6% |
| >16 years | 78.0% | 70.7% | 70.6% | 70.7% |

Demographics


Age Distribution




| Age (yrs) | All | | Male | | Female | |
|-----------|------------------|------|------|------|--------|------|
| | n | % | n | % | n | % |
| 0-3 | 33 | 7.4 | 16 | 6.7 | 17 | 8.4 |
| 4-7 | 62 | 14.0 | 32 | 13.3 | 30 | 14.8 |
| 8-11 | 47 | 10.6 | 24 | 10.0 | 23 | 11.3 |
| 12-15 | 54 | 12.2 | 31 | 12.9 | 23 | 11.3 |
| 16-19 | 49 | 11.1 | 28 | 11.7 | 21 | 10.3 |
| 20-23 | 48 | 10.8 | 29 | 12.1 | 19 | 9.4 |
| 24-27 | 29 | 6.5 | 13 | 5.4 | 16 | 7.9 |
| 28-31 | 33 | 7.4 | 18 | 7.5 | 15 | 7.4 |
| 32-35 | 23 | 5.2 | 12 | 5.0 | 11 | 5.4 |
| 36-39 | 11 | 2.5 | 7 | 2.9 | 4 | 2.0 |
| 40-43 | 16 | 3.6 | 10 | 4.2 | 6 | 3.0 |
| 44-47 | 11 | 2.5 | 7 | 2.9 | 4 | 2.0 |
| 48-51 | 7 | 1.6 | 4 | 1.7 | 3 | 1.5 |
| 52-55 | 4 | 0.9 | 2 | 0.8 | 2 | 1.0 |
| 56-59 | 4 | 0.9 | 1 | 0.4 | 3 | 1.5 |
| >=60 | 12 | 2.7 | 6 | 2.5 | 6 | 3.0 |
| Total | 443 | | 240 | | 203 | |
| Median | 18.1 years | | | | | |
| Range | 0.4 - 84.0 years | | | | | |

Over our first years of collecting registry data the median age of PWCF has increased with a corresponding increase in the proportion of adults.


Gender Distribution



Gender Distribution <16 years



Gender Distribution >16 years



| | All | | <16 years | | >16 years | |
|--------|-----|------|-----------|------|-----------|------|
| | n | % | n | % | n | % |
| Male | 240 | 54.2 | 103 | 52.6 | 137 | 55.5 |
| Female | 203 | 45.8 | 93 | 47.4 | 110 | 44.5 |
| Total | 443 | | 196 | | 247 | |

The gender distribution can become less even in adult years - in part because young women can have accelerated disease.

Genotype

429 (96.8%) of 443 patients have been genotyped with a recorded value.

| F508del Mutations | n | % |
|---------------------------------|-----|------|
| Homozygous F508del | 221 | 51.5 |
| Heterozygous F508del | 162 | 37.8 |
| No F508del or both unidentified | 46 | 10.7 |
| Total | 429 | |


| Mutations Identified | c.DNA Name | n | % |
|----------------------|---------------------|-----|------|
| F508del | c.1521_1523delCTT | 604 | 70.4 |
| G551D | c.1652G>A | 30 | 3.5 |
| G542X | c.1624G>T | 27 | 3.1 |
| R117H | c.350G>A | 21 | 2.4 |
| G85E | c.254G>A | 6 | 0.7 |
| N1303K | c.3909c>G | 5 | 0.6 |
| 3272-26A>G | c.3140-26A>G | 5 | 0.6 |
| ΔI507 | c.1519_1521delATC | 4 | 0.5 |
| 1717-1G->A | c.1585-1G>A | 4 | 0.5 |
| 3849+10kbC->T | c.3717+12191C>T | 4 | 0.5 |
| Q493X | c.1477C>T | 4 | 0.5 |
| 1898+1G->A | c.1766+1G>A | 3 | 0.3 |
| 2789+2insA | c.2657+2_2657+3insA | 2 | 0.2 |
| A455E | c.1364C>A | 3 | 0.3 |
| c.3718-2477C>T | c.3718-2477C>T | 3 | 0.3 |
| Other | | 88 | 10.3 |
| Unidentified | | 45 | 5.2 |
| | | 858 | |

Increasingly the genetic mutations will be presented named for their DNA abnormalities (column 2) standardised world-wide. We still know them best by what has come to be called their legacy names (column 1).

It is encouraging to see that the majority have had their genotype determined. This will become increasingly important as new genotype specific drugs potentially become available. As previously mentioned, here in NZ while F508 remains the dominant gene, this is seen less here than in registries from other English speaking countries where it is 85% to 92%, suggesting that our ethnic diversity may contribute less common genes.

Respiratory

Median FEV1 (% predicted) among patients >6 years
n = 283




| Age (yrs) | All | | Male | | Female | |
|-----------|-----|--------|------|--------|--------|--------|
| | n | median | n | median | n | median |
| 6-7 | 18 | 109.0 | 9 | 104.8 | 9 | 116.6 |
| 8-11 | 37 | 98.1 | 18 | 103.9 | 19 | 96.6 |
| 12-15 | 37 | 94.1 | 22 | 93.5 | 15 | 95.8 |
| 16-19 | 38 | 87.0 | 23 | 85.0 | 15 | 97.1 |
| 20-23 | 33 | 84.1 | 21 | 87.9 | 12 | 77.3 |
| 24-27 | 25 | 71.5 | 12 | 77.8 | 13 | 69.8 |
| 28-31 | 28 | 48.5 | 17 | 40.0 | 11 | 88.8 |
| 32-35 | 19 | 59.4 | 11 | 52.0 | 8 | 60.7 |
| 36-39 | 9 | 55.6 | 6 | 54.2 | 3 | 72.8 |
| 40-43 | 14 | 88.9 | 9 | 105.1 | 5 | 80.6 |
| 44-47 | 7 | 66.8 | 5 | 66.8 | 2 | 62.1 |
| 48-51 | 5 | 85.0 | 2 | 78.1 | 3 | 85.0 |
| 52-55 | 2 | 69.2 | 1 | 85.6 | 1 | 52.8 |
| 56-59 | 4 | 91.4 | 1 | 87.6 | 3 | 95.2 |
| >=60 | 7 | 61.7 | 4 | 64.2 | 3 | 61.5 |
| Total | 283 | | 161 | | 122 | |

The slope of lung function (FEV1) over time is very similar to the other registries with our target lung function being greater than 85% which is in keeping with the UK registry. Our median FEV1 for those <16 years and >16 years is comparative to other registries.

The spike in older ages reflects late diagnoses with CF reflecting a more mild or atypical disease, plus loss of those with severe disease. It is more obvious within the smaller numbers that we have in each age bracket in NZ. Other registries have presented the data as the percentage of children and adults with normal, mild, moderate or severely affected lung function.

Nutrition

Median BMI percentile among children 2-15years
n = 138




| Age (yrs) | BMI Percentile | |
|-----------|----------------|--------|
| | n | median |
| 2 | 1 | 12.3 |
| 3 | 10 | 80.8 |
| 4 | 12 | 77.8 |
| 5 | 14 | 71.7 |
| 6 | 11 | 57.3 |
| 7 | 10 | 66.9 |
| 8 | 13 | 68.0 |
| 9 | 11 | 44.8 |
| 10 | 10 | 52.9 |
| 11 | 8 | 51.4 |
| 12 | 11 | 42.9 |
| 13 | 8 | 57.3 |
| 14 | 11 | 69.9 |
| 15 | 8 | 74.8 |
| Total | 138 | |

The dotted line is the marker to target weight for height in children. It appears that we perform well in this parameter in NZ.


Median BMI values for >16 years

n = 201




| Age (yrs) | All | | Female | | Male | |
|--------------|------------|--------|-----------|--------|------------|--------|
| | n | median | n | median | n | median |
| 16-19 | 38 | 21.8 | 15 | 22.7 | 23 | 19.9 |
| 20-23 | 40 | 21.4 | 15 | 21.0 | 25 | 21.6 |
| 24-27 | 25 | 22.5 | 13 | 21.7 | 12 | 23.2 |
| 28-31 | 28 | 22.7 | 11 | 22.7 | 17 | 22.7 |
| 32-35 | 19 | 23.5 | 8 | 26.7 | 11 | 22.9 |
| 36-39 | 9 | 24.0 | 3 | 23.7 | 6 | 25.8 |
| 40-43 | 15 | 24.3 | 6 | 21.5 | 9 | 25.5 |
| 44-47 | 8 | 24.5 | 3 | 18.3 | 5 | 24.8 |
| 48-51 | 5 | 24.0 | 3 | 24.0 | 2 | 24.1 |
| 52-55 | 2 | 26.1 | 1 | 28.4 | 1 | 23.8 |
| 56-59 | 4 | 27.2 | 3 | 24.1 | 1 | 32.0 |
| >=60 | 8 | 25.5 | 4 | 28.6 | 4 | 22.7 |
| Total | 201 | | 85 | | 116 | |

Patients receiving supplemental feeding
 <16yrs n=155, >16yrs n=203,
 ALL n=358




Types of Supplemental Feeding
 (shown as % of those receiving supp.feeds)



| | <16 yrs, n = 155 | | | >16 yrs, n = 203 | | | All, n = 358 | | |
|----------------------|------------------|------|----------------|------------------|------|-----------------|--------------|------|-------------|
| | Yes | % | % <16yrs supp. | Yes | % | % >16 yrs supp. | Yes | % | % All supp. |
| Supplemental Feeding | 73 | | 47.1 | 111 | | 54.7 | 184 | | 51.4 |
| Nasogastric | 1 | 1.4 | 0.6 | 2 | 1.8 | 1.0 | 3 | 1.6 | 0.8 |
| Gastrostomy | 11 | 15.1 | 7.1 | 16 | 14.4 | 7.9 | 27 | 14.7 | 7.5 |
| Oral | 63 | 86.3 | 40.6 | 83 | 74.8 | 40.9 | 146 | 79.3 | 40.8 |

The early and high use of supplemental feeding may reflect on the overall good nutritional percentiles presented in previous graphs.

Medications




| Medication | <16 yrs, n = 155 | | >16 yrs, n = 203 | | All, n = 358 | |
|-----------------------------|------------------|------|------------------|------|--------------|------|
| | Yes | % | Yes | % | Yes | % |
| Dornase Alfa | 29 | 18.7 | 64 | 31.5 | 93 | 26.0 |
| Chronic Macrolide AB (Oral) | 15 | 9.7 | 76 | 37.4 | 91 | 25.4 |
| Hypertonic Saline | 98 | 63.2 | 97 | 47.8 | 195 | 54.5 |
| Aminoglycosides | 11 | 7.1 | 10 | 4.9 | 21 | 5.9 |
| Colistin | 5 | 3.2 | 17 | 8.4 | 22 | 6.1 |
| InhaledOther | 1 | 0.6 | 2 | 1.0 | 3 | 0.8 |

In New Zealand there is greater use of nebulised hypertonic saline, but less use of the other medications compared to that documented in other registries.

Microbiology

Culture Prevalence

<16yrs n=155, >16yrs n=203, ALL n=358



| | <16 yrs, n = 155 | | >16 yrs, n = 203 | | All, n = 358 | |
|---------------------------|------------------|------|------------------|------|--------------|------|
| | Yes | % | Yes | % | Yes | % |
| <i>P. aeruginosa</i> | 23 | 14.8 | 94 | 46.3 | 117 | 32.7 |
| <i>S. aureus</i> | 91 | 58.7 | 100 | 49.3 | 191 | 53.4 |
| MRSA | 9 | 5.8 | 11 | 5.4 | 20 | 5.6 |
| <i>B. cepacia</i> complex | 3 | 1.9 | 21 | 10.3 | 24 | 6.7 |
| <i>Mycobacteria</i> (NTB) | 3 | 1.9 | 3 | 1.5 | 6 | 1.7 |
| <i>S. maltophilia</i> | 21 | 13.5 | 10 | 4.9 | 31 | 8.7 |
| <i>Aspergillus</i> | 43 | 27.7 | 64 | 31.5 | 107 | 29.9 |
| <i>H. influenzae</i> | 71 | 45.8 | 36 | 17.7 | 107 | 29.9 |


Our levels of *Staphylococcus aureus* are higher than the registries that capture data as 'chronic infection', but similar to the USA which captures the data as 'ever' in the last year.

Our levels of *Pseudomonas aeruginosa* infections seem lower if 'ever' or 'intermittent' infections as well as 'chronic' infection are included. One goal in the UK is to have only 30% of children having *P. aeruginosa* at the time of transfer to adult clinic.

We have more *Burkholderia cepacia*, and less *Stenotrophomonas maltophilia* than elsewhere. We still have low levels of MRSA compared to other registry data but this appears to be increasing over recent years here. Not mentioned here is the division within the *Mycobacteria* categories - in the main we see *Mycobacteria avium intracellulare*, and while that is the same across countries, in some such as Australia they are reporting increased numbers of those with *Mycobacterium abscessus* - a more pathogenic organism.

It remains critical to check for *Mycobacterium* growth in sputum before commencing macrolide therapy and to review this at least annually. If *Mycobacteria* are present - macrolide therapy must be stopped.


Culture Prevalence by Age



| Age (yrs) | <i>P.aeruginosa</i> | | <i>S. aureus</i> | | MRSA | | <i>B. cepacia complex</i> | | <i>H. influenzae</i> | | <i>S. maltophilia</i> | | |
|--------------|---------------------|------------|------------------|------------|-------------|-----------|---------------------------|-----------|----------------------|------------|-----------------------|-----------|------------|
| | n | % | n | % | n | % | n | % | n | % | n | % | |
| <5 | 43 | 1 | 2.3 | 20 | 46.5 | 2 | 4.7 | 1 | 2.3 | 17 | 39.5 | 0 | 0.0 |
| 5-9 | 57 | 8 | 14.0 | 34 | 59.6 | 2 | 3.5 | 0 | 0.0 | 36 | 63.2 | 5 | 8.8 |
| 10-14 | 46 | 13 | 28.3 | 31 | 67.4 | 4 | 8.7 | 1 | 2.2 | 13 | 28.3 | 11 | 23.9 |
| 15-19 | 47 | 14 | 29.8 | 29 | 61.7 | 2 | 4.3 | 5 | 10.6 | 14 | 29.8 | 8 | 17.0 |
| 20-24 | 50 | 24 | 48.0 | 31 | 62.0 | 6 | 12.0 | 8 | 16.0 | 13 | 26.0 | 4 | 8.0 |
| 25-29 | 30 | 18 | 60.0 | 15 | 50.0 | 0 | 0.0 | 1 | 3.3 | 4 | 13.3 | 0 | 0.0 |
| 30-34 | 29 | 20 | 69.0 | 11 | 37.9 | 1 | 3.4 | 4 | 13.8 | 1 | 3.4 | 2 | 6.9 |
| 35-39 | 13 | 8 | 61.5 | 5 | 38.5 | 0 | 0.0 | 2 | 15.4 | 2 | 15.4 | 0 | 0.0 |
| 40-44 | 19 | 4 | 21.1 | 9 | 47.4 | 1 | 5.3 | 1 | 5.3 | 3 | 15.8 | 1 | 5.3 |
| 45-49 | 8 | 3 | 37.5 | 2 | 25.0 | 0 | 0.0 | 0 | 0.0 | 1 | 12.5 | 0 | 0.0 |
| >50 | 16 | 4 | 25.0 | 4 | 25.0 | 2 | 12.5 | 1 | 6.3 | 3 | 18.8 | 0 | 0.0 |
| Total | 358 | 117 | 32.7 | 191 | 53.4 | 20 | 5.6 | 24 | 6.7 | 107 | 29.9 | 31 | 8.7 |

The pattern of acquisition of these organisms with age are similar worldwide. The drop off in *P. aeruginosa* infection towards the older years reflects the more mild or atypical CF diagnosed in these older age brackets. It is more marked in this graph as it is based on the smaller numbers than elsewhere.

Culture Prevalence by Age



| Age (yrs) | Mycobacterium (NTB) | | Aspergillus | |
|-----------|---------------------|---|-------------|------|
| | n | % | n | % |
| <5 | 43 | 0 | 3 | 7.0 |
| 5-9 | 57 | 0 | 12 | 21.1 |
| 10-14 | 46 | 2 | 23 | 50.0 |
| 15-19 | 47 | 1 | 22 | 46.8 |
| 20-24 | 50 | 0 | 14 | 28.0 |
| 25-29 | 30 | 0 | 16 | 53.3 |
| 30-34 | 29 | 0 | 9 | 31.0 |
| 35-39 | 13 | 0 | 1 | 7.7 |
| 40-44 | 19 | 2 | 4 | 21.1 |
| 45-49 | 8 | 0 | 1 | 12.5 |
| >50 | 16 | 1 | 2 | 12.5 |
| Total | 358 | 6 | 107 | 29.9 |

Rates of *Aspergillus* presence in respiratory sections here are similar to that reported in Australia.

The presence of NTB seems low - not mentioned here is the division within the *Mycobacteria* categories - in the main we see *M. avium intracellulare*, and while that is the same across countries, in some such as Australia they are reporting increased numbers of those with *M. abscessus* - a more pathogenic organism.

Hospital & Home IVA Days

| Age | n | Home IV Days | | | | Hospital IV Days | | | | Total IVA Days |
|-------|-----|--------------|------|------------|----------|------------------|------|------------|----------|----------------|
| | | n | % | Total Days | Mean IVA | n | % | Total Days | Mean IVA | |
| 0-3 | 21 | 4 | 19.0 | 37 | 9.3 | 7 | 23.7 | 166 | 24 | 203 |
| 4-7 | 42 | 9 | 21.4 | 79 | 8.8 | 17 | 10.1 | 172 | 10 | 251 |
| 8-11 | 36 | 9 | 25.0 | 108 | 12.0 | 15 | 17.4 | 261 | 17 | 369 |
| 12-15 | 36 | 12 | 33.3 | 213 | 17.8 | 20 | 21.8 | 435 | 22 | 648 |
| 16-19 | 38 | 11 | 28.9 | 174 | 15.8 | 20 | 36.6 | 731 | 37 | 905 |
| 20-23 | 40 | 9 | 22.5 | 93 | 10.3 | 20 | 25.0 | 500 | 25 | 593 |
| 24-27 | 25 | 4 | 16.0 | 75 | 18.8 | 10 | 39.0 | 390 | 39 | 465 |
| 28-31 | 23 | 8 | 34.8 | 207 | 25.9 | 10 | 34.6 | 246 | 25 | 453 |
| 32-35 | 20 | 7 | 35.0 | 114 | 16.3 | 13 | 16.5 | 214 | 17 | 328 |
| 36-39 | 9 | 2 | 22.2 | 27 | 13.5 | 2 | 6.0 | 12 | 6 | 39 |
| 40-43 | 16 | 7 | 43.8 | 136 | 19.4 | 7 | 18.3 | 128 | 18 | 264 |
| 44-47 | 8 | 1 | 12.5 | 28 | 28.0 | 2 | 45.5 | 91 | 46 | 119 |
| 48-51 | 7 | 2 | 28.6 | 53 | 26.5 | 3 | 11.0 | 33 | 11 | 86 |
| >52 | 17 | 3 | 17.6 | 25 | 8.3 | 4 | 5.8 | 23 | 6 | 48 |
| | 338 | 88 | | 1369 | | 150 | | 3402 | | 4771 |


29% of intravenous antibiotic therapy was given in the home – now even in the very young. In part it depends on the ability to have excellent intravenous access, the severity of the current infection in the individual, and the home environment at any particular time.

One factor that is missing when using home IV therapy is the ability to deliver professional physiotherapy which is equally important in overcoming an exacerbation.

Airway Clearance Techniques

Primary Airway Clearance Technique <16 years

n = 155 (Some patients may have used more than one technique)



* number of individuals employing each technique at least once in the year.
Data collected from 155 patients


| Technique | <16 years | |
|---|-----------|------|
| Exercise | 21 | 13.5 |
| Positive Expiratory Pressure | 94 | 60.6 |
| Oscillating PEP (e.g.: Flutter, Acapella, IPV) | 7 | 4.5 |
| Forced Expiration Techniques (e.g. huff cough, active cycle breathing, autogenic drainage) | 4 | 2.6 |
| High Frequency Chest Wall Compression (e.g.: vest) | 3 | 1.9 |
| Modified Postural Drainage | 66 | 42.6 |
| None | 6 | 3.9 |
| Total | 201 | |

There are a variety of techniques used as a first option for airway clearance, with nearly half using some airway resistance device.

The percentage of children and young people using no airway clearance technique has generally decreased over the years that we have been collecting the data but with a slight increase from 2.3% last year to 3.9% this year.

Primary Airway Clearance Technique >16 years

n = 203 (Some patients may have used more than one technique)



* number of individuals employing each technique at least once in the year.
Data collected from 203 patients


| Technique | <u>>16 years</u> | |
|---|---------------------|------|
| Exercise | 72 | 35.5 |
| Positive Expiratory Pressure | 46 | 22.7 |
| Oscillating PEP (e.g.: Flutter, Acapella, IPV) | 33 | 16.3 |
| Forced Expiration Techniques (e.g. huff cough, active cycle breathing, autogenic drainage) | 40 | 19.7 |
| High Frequency Chest Wall Compression (e.g.: vest) | 1 | 0.5 |
| Modified Postural Drainage | 4 | 2.0 |
| None | 27 | 13.3 |
| Total | 223 | |

More adults than children and younger people use exercise as their primary airway clearance technique, with a similar number across the components using resistance devices.

Those using no airway clearance are higher in the adults than in children.

Secondary Airway Clearance Techniques

<16 years n=166, >16 years n = 186




Data collected in 166 <16 years, 186 >16 years; Some patients may use more than one technique

| Technique | <16 years | | >16 years | |
|---|-----------|------|-----------|------|
| | n | % | n | % |
| Exercise | 94 | 60.6 | 73 | 36.0 |
| Positive Expiratory Pressure | 24 | 15.5 | 11 | 5.4 |
| Oscillating PEP (eg: Flutter, Acapella, IPV) | 9 | 5.8 | 13 | 6.4 |
| Forced Expiration Techniques (eg:huff cough, active cyce breathing, autogenic drainage) | 2 | 1.3 | 24 | 11.8 |
| High Frequency Chest Wall Compression (eg: vest) | 9 | 5.8 | 1 | 0.5 |
| Modified Postural Drainage | 24 | 15.5 | 5 | 2.5 |
| Total | 162 | | 127 | |

Exercise remains a strong component of airway clearance

CF-Related Diabetes


CF Related Diabetes
n = 332



| Age (years) | Age n | CFRD n | % Age Group | %CF Population |
|--------------|------------|-----------|-------------|----------------|
| 0-3 | 25 | 0 | 0.0 | 0.0 |
| 4-7 | 44 | 0 | 0.0 | 0.0 |
| 8-11 | 35 | 3 | 8.6 | 0.9 |
| 12-15 | 36 | 8 | 22.2 | 2.4 |
| 16-19 | 36 | 7 | 19.4 | 2.1 |
| 20-23 | 39 | 5 | 12.8 | 1.5 |
| 24-27 | 23 | 3 | 13.0 | 0.9 |
| 28-31 | 23 | 3 | 13.0 | 0.9 |
| 32-35 | 19 | 3 | 15.8 | 0.9 |
| 36-39 | 9 | 1 | 11.1 | 0.3 |
| 40-43 | 15 | 4 | 26.7 | 1.2 |
| 44-47 | 7 | 2 | 28.6 | 0.6 |
| 48-51 | 6 | 2 | 33.3 | 0.6 |
| 52-55 | 2 | 0 | 0.0 | 0.0 |
| 56-59 | 4 | 0 | 0.0 | 0.0 |
| >=60 | 9 | 0 | 0.0 | 0.0 |
| Total | 332 | 41 | | 12.3 |

Occurrence of CF Related Diabetes

n = 352



| | n | CFRD n | % | <16 years | % | >16 years | % |
|---------|-----|--------|------|-----------|-----|-----------|------|
| Females | 145 | 20 | 13.8 | 5 | 3.4 | 15 | 10.3 |
| Males | 187 | 21 | 14.5 | 6 | 4.1 | 15 | 10.3 |
| Total | 332 | 41 | 28.3 | 11 | 7.6 | 30 | 20.7 |

The overall percentage of persons with CF affected by CFRD is similar to other reports, but the younger age group seems less with similar results since collecting the data. A review of the timeliness and accuracy of our screening may be appropriate.

Glossary of Terms

| | |
|------------|---|
| FEV1 | Measurement of lung capacity as forced expired volume in one second |
| BMI | Body Mass Index: measurement of weight relative to height |
| N (n) | Total number of people in a dataset |
| Median | Middle number in a numerically arranged range of numbers |
| Range | Upper and lower values in a dataset |
| Paediatric | 0 – 16 years of age |
| Adult | >16 years of age |

| | |
|------------------------------|--|
| Principal Investigator | Dr Richard Laing MBChB, FRACP |
| Chair – Steering Committee | Assoc Prof Catherine Byrnes MBChB, FRACP, MD |
| Project Administrator | Julie Clemett, Administration Manager CFNZ |
| Project IT Manager | Andrew Watson, CDHB |
| Project Medical Statistician | Dr Chris Frampton, Christchurch School of Medicine |

All enquiries regarding this Data Registry should be forwarded in the first instance, to:

Julie Clemett
CFNZ
PO Box 8241, Riccarton
Christchurch 8440
julie@cfnz.org.nz
Phone 03 341 8014



CYSTIC FIBROSIS NZ

Creating Better Tomorrows